ANI Pharmaceuticals (ANIP) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and Concert Pharmaceuticals (NASDAQ:CNCE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.

Does the media favor ANIP or CNCE?

In the previous week, ANI Pharmaceuticals had 4 more articles in the media than Concert Pharmaceuticals. MarketBeat recorded 4 mentions for ANI Pharmaceuticals and 0 mentions for Concert Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.28 beat Concert Pharmaceuticals' score of 0.40 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ANI Pharmaceuticals	Positive
Concert Pharmaceuticals	Neutral

Which has more risk and volatility, ANIP or CNCE?

ANI Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Concert Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Is ANIP or CNCE more profitable?

ANI Pharmaceuticals has a net margin of 5.01% compared to Concert Pharmaceuticals' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 15.64% beat Concert Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	5.01%	15.64%	7.63%
Concert Pharmaceuticals	N/A	-109.43%	-76.65%

Does the MarketBeat Community prefer ANIP or CNCE?

Concert Pharmaceuticals received 78 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. However, 64.47% of users gave ANI Pharmaceuticals an outperform vote while only 61.58% of users gave Concert Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ANI Pharmaceuticals	Outperform Votes 430 64.47%	Underperform Votes 237 35.53%
Concert Pharmaceuticals	Outperform Votes 508 61.58%	Underperform Votes 317 38.42%

Do analysts prefer ANIP or CNCE?

ANI Pharmaceuticals presently has a consensus target price of $78.80, suggesting a potential upside of 38.63%. Given ANI Pharmaceuticals' higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Concert Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Concert Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Do institutionals & insiders hold more shares of ANIP or CNCE?

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.6% of Concert Pharmaceuticals shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 11.3% of Concert Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has preferable earnings and valuation, ANIP or CNCE?

ANI Pharmaceuticals has higher revenue and earnings than Concert Pharmaceuticals. Concert Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$538.95M	2.21	$18.78M	$1.60	35.46
Concert Pharmaceuticals	$32.58M	12.32	-$80.05M	-$3.21	-2.61

Summary

ANI Pharmaceuticals beats Concert Pharmaceuticals on 15 of the 17 factors compared between the two stocks.